NCT04710576 2026-03-16AGAVE-201Syndax PharmaceuticalsPhase 2 Active not recruiting241 enrolled 11 charts 1 FDA
NCT05491226 2025-08-27Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationCedars-Sinai Medical CenterPhase 2 Active not recruiting35 enrolled